ALIMA Tests Pre-Symptomatic Pill to Halt Bundibugyo Ebola Spread
A clinical trial led by ALIMA is testing a preventive pill for the Bundibugyo Ebola virus in the Democratic Republic of the Congo. The study aims to protect uninfected individuals before symptoms appear, distinct from vaccines or curative treatments. While the outbreak has surpassed 8,000 cases, this trial offers a potential new tool to break infection chains.